Tirzepatide has shown promise for treatment of obesity but its effects in heart failure are unknown. Using real-world data from over 14,000 patients, the authors show that tirzepatide is associated with lower risks of death, heart failure worsening, cardiovascular events, and kidney complications in people with preserved ejection fraction heart failure.
- Yu-Min Lin
- Kuang-Ming Liao
- Chih-Cheng Lai
